



Published today in Nature Medicine: Peptomyc's first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial

Barcelona, 6th of February 2024

Peptomyc is proud to announce that the results of the MYCure clinical trial have just been published in Nature Medicine (<https://www.nature.com/articles/s41591-024-02805-1>), demonstrating the unique potential of our lead first-in-class MYC inhibitor, OMO-103, to treat multiple oncological indications. Peptomyc takes pride in pioneering the blockade of a most-wanted target in cancer, and we believe this encouraging data, along with our preclinical findings, underscore the importance of MYC inhibition in the treatment of cancer. Thanks to the whole team, to our investors and collaborators for believing in this work and for this huge milestone!